カテゴリ： Market Research Future, 世界, 医療/バイオ

食道扁平上皮がんのグローバル市場（～2030）：診断、治療法

■ 英語タイトル：Global Esophageal Squamous Cell Carcinoma Market Research Report Forecast till 2030

調査会社Market Research Future社が発行したリサーチレポート（データ管理コード：MRF23DCB014）■ 発行会社/調査会社：Market Research Future
■ 商品コード：MRF23DCB014
■ 発行日：2023年11月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：128
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール
■ 販売価格オプション（消費税別）
Single User（印刷不可、Online Access）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Enterprisewide Price（印刷可）USD7,250 ⇒換算￥1,102,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Research Future社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[食道扁平上皮がんのグローバル市場（～2030）：診断、治療法]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

食道扁平上皮がんの市場調査レポート：2030年までの予測
市場概要
食道扁平上皮がん市場は、調査期間中に8.16%のCAGRを記録すると予測されています。アカラシアの罹患者数の増加、研究演習やアイテムの支持の拡大、社会的認知度の上昇が市場発展の原動力となっています。
アカラシア罹患者は食道扁平上皮がんに罹患する確率が高いため、アカラシア罹患者の増加も市場発展に寄与しています。日記のArchives of Throatによると、毎年10万人あたり9〜10人がアカラシアを経験しているとのことです。
また、世界悪性腫瘍研究機構（Global Organization for Research on Malignant Growth）によると、この割合は食道扁平上皮がんの確率の15倍と数倍になります。従って、アカラシアの蔓延の拡大は、世界の食道扁平上皮がんの市場開発にストレートに影響を与えるでしょう。

市場セグメント
食道扁平上皮がん市場は、診断と治療に基づいてセグメント化され、診断はさらに内視鏡検査、CTスキャン、エソファグラム、陽電子放出断層撮影（PET）、その他にセグメント化されます。
食道扁平上皮がん市場は、病院、専門センター、その他を含むエンドユーザーに基づいてセグメンテーションされます。

地域別洞察
北米の食道扁平上皮がん市場は、2022年に最大の市場シェアを占めました。これは、食道扁平上皮がん治療市場への関心を高めている食道疾患の蔓延が増加しているためです。加えて、より良い治療オプションに対する重要な参加者の思惑が高まっていることも、同様に北米市場の発展を促進すると予想されています。
ヨーロッパの食道扁平上皮がん市場は第2位の市場シェアを占めていますが、これは喫煙、タバコ、飲酒傾向の高まりが食道扁平上皮がんの高度な治療選択肢に対する関心を高めているためです。さらに、医療サービスの利用が増加していることも、同様に市場の発展に寄与すると予想されています。
アジア太平洋の食道扁平上皮がん市場は、2023年から2030年まで重要なオファーで発展することになっています。これは、例えば食道扁平上皮がんの頻度が上昇していること、タバコを吸う人口が多いこと、酒類を好む人口が多いことなどの要素が市場発展をサポートすると予想されているためです。さらに、実際の惰性と不運な生活様式の上昇も、地方市場の発展をサポートすることが期待されています。さらに、食道扁平上皮がんの中国市場は最大の市場提供を保持することになっており、残りのアジア太平洋市場は通常の最も急速に発展している地区です。
その他の地域は中東、アフリカ、ラテンアメリカに区分されます。前述した地域の市場は、確かな疫学的要因や、医療サービスオフィスのさらなる発展、健全な生活に対する意識の拡大により、おそらく発展が観察されるでしょう。

主要企業
食道扁平上皮がん市場の主要企業には、Hoffmann-La Roche Ltd、AstraZeneca、Chia Tai Tianqing Pharmaceutical Group Co. Ltd.、Seagen Inc.、Eli Lilly and Company、Glaxosmithkline Plc、Novartis AG、Beijing Shenzhou、Cell Biotechnology Group Co.などが含まれます。

1.　エグゼクティブサマリー
2.　イントロダクション
3.　調査方法
4.　市場動向
5.　市場要因分析
6.　世界の食道扁平上皮がん市場規模：診断・治療法別
7.　世界の食道扁平上皮がん市場規模：エンドユーザー別
8.　世界の食道扁平上皮がん市場規模：地域別
9.　競争状況
10.　企業情報
11.　付録

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF ACHALASIA

4.2.2 INCREASED RESEARCH ACTIVITIES AND PRODUCT APPROVALS

4.2.3 RISING PUBLIC AWARENESS

4.3 RESTRAINTS

4.3.1 HIGH COST OF TREATMENT

4.3.2 SIDE EFFECTS OF ESOPHAGEAL CANCER DRUGS

4.4 OPPORTUNITIES

4.4.1 RISE IN CLINICAL TRIALS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D & DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

5.3.1 IMPACT ON DEMAND

5.3.2 IMPACT ON SUPPLY CHAIN

5.3.3 IMPACT ON MARKET PLAYERS)

5.4 TOTAL NUMBER OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS, BY REGION

5.5 ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENT FORECAST, (2018-2024)

5.6 STANDARD OF CARE (SOC) FOR THE TREATMENT

5.6.1 STANDARD OF CARE (SOC) FOR SURGERY:

5.6.2 STANDARD OF CARE (SOC) FOR CHEMOTHERAPY:

5.6.3 STANDARD OF CARE (SOC) FOR RADIOTHERAPY:

5.6.4 STANDARD OF CARE (SOC) FOR THE IMMUNOTHERAPY:

5.6.5 STANDARD OF CARE (SOC) FOR OTHER TREATMENTS

6 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET BY DIAGNOSIS & TREATMENT

6.1 OVERVIEW

6.2 DIAGNOSIS

6.2.1 ENDOSCOPY

6.2.2 CT SCAN

6.2.3 ESOPHAGRAM

6.2.4 POSITRON EMISSION TOMOGRAPHY (PET)

6.2.5 OTHERS

6.3 TREATMENT

6.3.1 SURGERY

6.3.2 CHEMOTHERAPY

6.3.3 RADIOTHERAPY

6.3.4 IMMUNOTHERAPY

6.3.5 OTHERS

7 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET BY END USER

7.1 OVERVIEW

7.1.1 HOSPITALS

7.1.2 SPECIALTY CENTERS

7.1.3 OTHERS

8 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY REGION

8.1 GLOBAL

8.2 NORTH AMERICA

8.2.1 US

8.2.2 CANADA

8.3 EUROPE

8.3.1 GERMANY

8.3.2 UK

8.3.3 FRANCE

8.3.4 ITALY

8.3.5 SPAIN

8.3.6 REST OF EUROPE

8.4 ASIA-PACIFIC

8.4.1 CHINA

8.4.2 INDIA

8.4.3 JAPAN

8.4.4 AUSTRALIA

8.4.5 SOUTH KOREA

8.4.6 REST OF ASIA-PACIFIC

8.5 REST OF THE WORLD

8.5.1 MIDDLE EAST

8.5.2 AFRICA

8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 COMPETITIVE BENCHMARKING

9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.5.1 PRODUCT LAUNCHES/PRODUCT APPROVALS

9.6 FINANCIAL MATRIX

9.6.1 SALES (USD MILLION), 2021

9.6.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

10 COMPANY PROFILES

10.1 F. HOFFMANN-LA ROCHE LTD

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 PRODUCTS OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 ASTRAZENECA

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

10.3.1 COMPANY OVERVIEWS

10.3.2 FINANCIAL OVERVIEW

10.3.3 PRODUCTS OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 KEY STRATEGIES

10.4 SEAGEN INC.

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 KEY STRATEGIES

10.5 ELI LILLY AND COMPANY

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 SWOT ANALYSIS

10.5.6 KEY STRATEGIES

10.6 GLAXOSMITHKLINE PLC

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL OVERVIEW

10.6.3 PRODUCTS OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 SWOT ANALYSIS

10.6.6 KEY STRATEGIES

10.7 NOVARTIS AG

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 SWOT ANALYSIS

10.7.6 KEY STRATEGIES

10.8 BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 KEY STRATEGIES

10.9 JACOBIO PHARMACEUTICALS GROUP CO., LTD.

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 4 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY REGION, 2018–2030 (USD MILLION)

TABLE 5 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR ENDOSCOPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 7 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR CT SCAN, BY REGION, 2018–2030 (USD MILLION)

TABLE 8 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR ESOPHAGRAM, BY REGION, 2018–2030 (USD MILLION)

TABLE 9 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR POSITRON EMISSION TOMOGRAPHY (PET), BY REGION, 2018–2030 (USD MILLION)

TABLE 10 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 11 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR CHEMOTHERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR RADIOTHERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR IMMUNOTHERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 18 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 19 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR HOSPITALS, BY REGION, 2018–2030 (USD MILLION)

TABLE 20 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR SPECIALTY CENTERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 21 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 22 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 23 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 24 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 25 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 26 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 27 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 28 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 29 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 30 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 31 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 32 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 33 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 34 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 35 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 36 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 37 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 38 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 39 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 40 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 41 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 42 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 43 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 44 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 45 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 46 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 47 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 48 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 49 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 50 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 51 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 52 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 53 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 54 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 55 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 56 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 57 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 58 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 59 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 60 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 61 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 62 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 63 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 64 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 65 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 66 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 67 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 68 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 69 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 70 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 71 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 72 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 73 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 74 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 75 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 76 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 77 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 78 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 79 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 80 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 81 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 82 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 83 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 84 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 85 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 86 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 87 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 88 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 89 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 90 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 91 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 92 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 93 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 94 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 95 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 96 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 97 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 98 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 99 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 100 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 101 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 102 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 103 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 104 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 105 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 106 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 107 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 108 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 109 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 110 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 111 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 112 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 113 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 114 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 115 MAJOR PLAYERS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

TABLE 116 MOST ACTIVE PLAYER IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

TABLE 117 PRODUCT LAUNCHES/PRODUCT APPROVALS

TABLE 118 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED

TABLE 119 ASTRAZENECA: PRODUCTS OFFERED

TABLE 120 ASTRAZENECA: KEY DEVELOPMENTS

TABLE 121 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED

TABLE 122 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.: KEY DEVELOPMENTS

TABLE 123 SEAGEN INC: PRODUCTS OFFERED

TABLE 124 SEAGEN INC.: KEY DEVELOPMENTS

TABLE 125 ELI LILLY AND COMPANY: PRODUCTS OFFERED

TABLE 126 ELI LILLY AND COMPANY: KEY DEVELOPMENTS

TABLE 127 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED

TABLE 128 NOVARTIS AG: PRODUCTS OFFERED

TABLE 129 BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.: PRODUCTS OFFERED

TABLE 130 JACOBIO PHARMACEUTICALS GROUP CO., LTD.: PRODUCTS OFFERED


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 扁平上皮癌（SCC）抗原定量キットのグローバル市場予測2023-2029
  • 世界の幹細胞製造市場（～2030）
  • 世界の膵臓がん診断市場2023-2030：市場規模、シェア、動向分析
  • 遺伝子編集の世界市場（〜2030）
  • マイクロニードルの世界市場（〜2030）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MRF23DCB014 )"食道扁平上皮がんのグローバル市場（～2030）：診断、治療法" (英文：Global Esophageal Squamous Cell Carcinoma Market Research Report Forecast till 2030)はMarket Research Future社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。